Maravai LifeSciences Holdings, Inc. (MRVI)
After hours:
| Previous close | 7.61 |
| Open | 7.58 |
| Bid | 7.27 x 300 |
| Ask | 7.32 x 600 |
| Day's range | 7.19 - 7.61 |
| 52-week range | 4.52 - 16.62 |
| Volume | |
| Avg. volume | 2,791,238 |
| Market cap | 1.835B |
| Beta (5Y monthly) | 0.01 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.90 |
| Earnings date | 08 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 9.78 |
Business WireTriLink BioTechnologies® Announces New San Diego Facility for Late Phase mRNA Drug Substance Production
SAN DIEGO, April 18, 2024--TriLink BioTechnologies® Announces New San Diego Facility for Late Phase mRNA Drug Substance Production
GlobeNewswireMaravai LifeSciences To Host Earnings Conference Call on Wednesday, May 8, 2024
SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its first quarter 2024 financial and operating results after the market closes on Wednesday, May 8, 2024, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial (888) 596-4144 or (646) 968-2525 a
Insider MonkeyShould You Sell Maravai LifeSciences (MRVI)?
ClearBridge Investments, an investment management firm, released its fourth-quarter 2023 “Mid Cap Strategy” investor letter, which can be downloaded here. As a late-year rally was fueled by confidence about an economic soft landing, a dovish flip by the Fed, and broader market performance, mid-cap stocks saw strong gains. Due to an inconstant industrial and consumer discretionary […]
